Logest - Instructions For Use, Indications, Doses, Analogues

Table of contents:

Logest - Instructions For Use, Indications, Doses, Analogues
Logest - Instructions For Use, Indications, Doses, Analogues

Video: Logest - Instructions For Use, Indications, Doses, Analogues

Video: Logest - Instructions For Use, Indications, Doses, Analogues
Video: Логест таблетки - видео инструкция, показания, описание, отзывы - Этинилэстрадиол, Гестоден 2023, September


Instructions for use:

  1. 1. Release form and composition
  2. 2. Indications for use
  3. 3. Contraindications
  4. 4. Method of application and dosage
  5. 5. Side effects
  6. 6. Special instructions
  7. 7. Drug interactions
  8. 8. Analogs
  9. 9. Terms and conditions of storage
  10. 10. Terms of dispensing from pharmacies

Prices in online pharmacies:

from 718 rub.


Film-coated tablets, Logest
Film-coated tablets, Logest

Logest is a low-dose monophasic combined oral contraceptive estrogen-progestogen drug.

Release form and composition

Dosage forms:

  • Film-coated tablets: round, white (21 pcs. In a blister, in a cardboard box 1 or 3 blisters);
  • Dragee: round, white (21 pcs. In a blister, in a cardboard box 1 or 3 blisters).

Content of active ingredients of Logest in 1 tablet or 1 tablet:

  • Gestodene - 0.075 mg;
  • Ethinylestradiol - 0.02 mg.

Excipients: corn starch, polyvidone 25,000, lactose monohydrate, sucrose, polyvidone 700,000, calcium carbonate, macrogol 6000, mountain wax glycolic, magnesium stearate, talc.

Indications for use

The use of Logest is indicated for oral contraception.


  • Angina pectoris, transient ischemic attacks and other conditions preceding thrombosis (including history);
  • Venous and arterial thrombosis, including thromboembolism of the branches of the pulmonary artery, deep vein thrombosis of the lower extremities, cerebrovascular disorders, myocardial infarction, including a history;
  • Multiple or severe risk factors for arterial or venous thrombosis;
  • Diabetes mellitus with vascular complications;
  • Pancreatitis with severe hypertriglyceridemia (including history);
  • Benign or malignant liver tumors (including history);
  • Severe forms of liver disease, jaundice, including a history (until the normalization of liver tests);
  • Migraine with focal neurological symptoms (including history);
  • Vaginal bleeding of unknown etiology;
  • Hormone-dependent malignant pathologies of the mammary glands or genitals (including history);
  • The period of pregnancy (or the assumption of its presence) and breastfeeding;
  • Intolerance to the components of the drug.

With caution, carefully weighing the expected benefits and potential health risks, it is recommended to prescribe Logest to women in the presence of the following risk factors: uterine fibroids, fibrocystic breast disease, smoking, thrombosis, the presence of one of the closest relatives at a young age, myocardial infarction, cerebral disorders circulatory system or breast cancer, obesity, dyslipoproteinemia, migraine (with no focal neurological symptoms), heart valve pathology, arterial hypertension, cardiac arrhythmias, serious surgery, prolonged immobilization, extensive trauma, systemic lupus erythematosus, liver disease, diabetes mellitus without vascular complications, hemolytic uremic syndrome, ulcerative colitis, Crohn's disease, phlebitis of superficial veins, sickle cell anemia,hypertriglyceridemia.

In addition, a doctor's consultation is required before taking the drug for patients who, against the background of previous use of sex hormones or during pregnancy, first developed or worsened pathologies such as cholestasis, jaundice, gallbladder disease, porphyria, otosclerosis with hearing impairment, Sydenham's chorea, herpes during pregnancy.

It should be borne in mind that with hereditary angioedema, exogenous estrogens can increase or cause symptoms of angioedema.

Method of administration and dosage

Logest is taken orally with plenty of water.

Dosage regimen: from the first day of the menstrual cycle, 1 tablet or dragee per day (using the drug from the cell corresponding to the day of the week), always at the same time for 21 days. This is followed by a break of 7 days, during this period, menstrual bleeding usually begins on days 2-3. On the 8th day after the end of taking the tablets (dragees) from the first blister, even if the withdrawal bleeding has not ended, you should start taking the drug from the next blister at the set time.

When you start taking the drug from the second to the fifth day of the menstrual cycle, it is recommended to additionally use a barrier method of contraception during the first 7 days of using tablets or dragees from the first blister.

When switching from previous oral contraception, using a contraceptive patch or vaginal ring, it is preferable to start taking Logest: the next day after the last hormone-containing tablet of the previous drug (including 21 tablets), but not later than the next day after the seven-day break or after the last inactive tablet from the 28 tablets; on the day of removing the patch or vaginal ring, but no later than the expected date of sticking a new patch or inserting a new ring.

A woman can switch from gestagen-containing mini-pili contraceptives without a break (any day), an implant or an intrauterine contraceptive (Mirena) that releases a gestagen - on the day of their removal, an injection form - on the day of the intended next injection. In each case, it is necessary to additionally use barrier methods of contraception during the first 7 days.

A woman can start taking the drug after an abortion in the first trimester of pregnancy on the day of surgery without using additional contraceptive measures.

It is recommended to start taking the drug after an abortion in the second trimester of pregnancy or childbirth on days 21-28 after surgery or childbirth if there is no breastfeeding. At a later start of oral contraception, taking pills or tablets during the first 7 days should be accompanied by additional methods of contraception. If during the period after an abortion or childbirth, a woman had sexual intercourse, it is necessary to exclude the presence of pregnancy or start taking Logesta with the beginning of the first menstruation.

Contraceptive protection depends on the regularity of taking the drug.

If you are late in taking the next pill (dragee) less than 12 hours, contraception is not violated. You should take the missed dose of the drug as soon as you remember and continue taking it as usual.

Contraceptive protection is reduced if the appointment is more than 12 hours late. The closer the next dose is skipped to a seven-day break and the more tablets (pills) are missed, the more the likelihood of pregnancy increases. The interruption in admission should never exceed 7 days. The recommended dosage regimen should always be followed, since to achieve the required suppression of the hypothalamic-pituitary-ovarian regulation, 7 days of continuous administration of the drug are required.

In case of an accidental delay in taking at the set time by more than 12 hours (more than 36 hours from the moment of taking the last dose) in the first week of using Logest, the missed pill (pill) must be taken as soon as you remember, even if you have to take 2 doses at the same time. Further, the drug is taken as usual. Over the next 7 days, you should use additional methods of contraception. If you have had sexual intercourse during the previous week before the skip, there is a chance of conception.

If the appointment is more than 12 hours late in the second week of therapy, the drug should be taken immediately, even if it means taking 2 tablets (pills) at the same time. The following tablets (pills) are taken at the set time. If in the last 7 days before being late the drug was taken without violating the regimen, additional barrier contraceptive measures are not required. If the regimen is violated or more than two tablets (pills) are missed, barrier methods of contraception are required during the next 7 days of taking the drug.

If the next dose is missed in the third week of therapy, the reliability of contraception is at great risk due to the next 7 days of interruption in admission. Subject to the regularity of taking the previous 7 tablets (pills), additional barrier methods are not required. Having taken the missed dose, you can continue taking the drug from the current blister at the set time, and without making a seven-day break, start taking the drug from the next blister. In this case, menstrual bleeding until the end of the next blister is unlikely; spotting or breakthrough bleeding may occur.

The second option for skipping a tablet (dragee) in the third week of therapy is to interrupt the drug intake from the current blister and a premature seven-day break (including the day of skipping) and continue using from the next blister according to the recommendations.

In the absence of withdrawal bleeding in the interval between taking the drug against the background of missing tablets (pills), you should consult a doctor to exclude pregnancy.

In case of vomiting or diarrhea within 4 hours from the moment of taking the dose of the drug, due to the risk of incomplete absorption, it is necessary to take the measures provided in the recommendations when skipping the dose.

If you wish to delay the onset of withdrawal bleeding, you should continue taking Logesta from the next blister after the completion of the previous blister without interruption. You can continue taking until all the tablets (pills) in the blister are complete. During this period, spotting or breakthrough uterine bleeding may occur. After a seven-day break, you should continue using the drug from a new blister.

To change the day of onset of withdrawal bleeding to the desired day of the week, the next break should be shortened by the required number of days. The probability of no withdrawal bleeding is the higher, the shorter the interruption in admission, at the same time, the risk of spotting bleeding and breakthrough bleeding increases when taking the drug from the next blister.

Side effects

  • Reproductive system: sometimes - spotting during the period of taking the drug during the first months, changes in vaginal secretion;
  • Nervous system: sometimes - headache, decreased mood, migraine;
  • Digestive system: sometimes - vomiting, nausea;
  • Endocrine system: sometimes - an increase and a feeling of tension in the mammary glands, a change in body weight, a decrease / increase in libido;
  • Others: possibly - fluid retention in the body, impaired tolerance of contact lenses, the development of allergic reactions.

special instructions

Before starting to use the drug, the patient must undergo a complete gynecological (including examination of the mammary glands and cytological examination of cervical mucus) and general medical examination, to exclude violations of the blood coagulation process and pregnancy.

It should be borne in mind that while taking the drug in women over 35 years old and smoking, the risk of arterial thrombosis increases.

The likelihood of developing thrombosis is increased with obesity, arterial hypertension, atrial fibrillation, heart valve disease, a burdened family history, dyslipoproteinemia.

Due to the risk of thrombosis, the drug should be discontinued 6 weeks before the planned surgery and during prolonged immobilization. Oral combined contraception should be resumed after the end of immobilization after 2 weeks.

In case of edema and pain along the veins in the lower extremities, sudden shortness of breath, acute pain and a feeling of heaviness in the chest, you must stop taking the pills (pills) and consult a doctor.

Against the background of the use of hormonal contraceptives, it is possible to change the usual menstrual cycle, the properties of cervical mucus, and rectal temperature.

In the event of severe pain in the lower abdomen, continuous itching, migraine, severe headaches, severe depression, a significant increase in blood pressure, sudden changes in hearing, visual perception or speech, increased frequency of seizures, the drug should be canceled and an appropriate examination should be carried out.

In the period of the first months of adaptation of the body, the appearance of intermenstrual minor spotting is allowed, in case of an increase in their intensity or appearance in a later period of Logesta's use, you should consult a doctor.

If there is no withdrawal bleeding during the seven-day break in taking the drug, you must consult a doctor before taking the pills (pills) from a new blister.

With the simultaneous administration of drugs that affect the effectiveness of Logesta, it is recommended to use additional barrier contraceptives during the treatment period and the next 7 days, and with rifampicin therapy - 4 weeks after the end of admission.

Patients prone to chloasma are advised to avoid direct sunlight while using the drug.

Drug interactions

Concomitant therapy with other drugs may cause a decrease in the contraceptive effectiveness of oral contraceptives and / or breakthrough bleeding. During this period, it is recommended to additionally use barrier or other methods of contraception.

The effectiveness of Logest decreases with the simultaneous use of ampicillin, rifampicin, tetracyclines, non-steroidal anti-inflammatory drugs, griseofulvin, phenytoin, carbamazepine, phenobarbital.

When prescribing other drugs, a woman should inform the doctor about taking a combined oral contraceptive estrogen-progestin agent.


Analogues of Logest are: Artisia, Gestarella, Lindinet 20, Lindinet 30, Femoden.

Terms and conditions of storage

Keep out of the reach of children:

  • Tablets - at temperatures up to 25 ° C, in a dark place;
  • Dragee - at room temperature.

Shelf life: tablets - 3 years, pills - 4 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Logest: prices in online pharmacies

Drug name



Logest dragee 21 pcs.

718 RUB


Logest 75 mcg + 20 mcg coated tablets 21 pcs.

718 RUB


Logest 75 mcg + 20 mcg film-coated tablets 63 pcs.

1790 RUB


Logest dragee 63 pcs.

1843 RUB


Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!